Listen "ASH 2025"
Episode Synopsis
ASH 2025 Highlights:
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma
Paradigm: HMA + Ven vs. 7+3 or CPX-351
Denosumab safety & dosing in Multiply Myeloma and renal dysfunction
Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
More episodes of the podcast OncoPharm
Iberdomide
20/08/2026
Kidney Cancer in a Nutshell
13/08/2026
Small Cell Lung Cancer and CINV Updates
06/08/2026
Zidesamtinib & PPIs in Pacific
30/07/2026
Gedatolisib et al
23/07/2026
Endurance Part 2
16/07/2026
A Decade of CAR-T, Ocra-T, & POLARGO
09/07/2026
Breast Cancer Updates and T-Cell Stemness
25/06/2026
ASCO '26
11/06/2026
